Clinical Trial Update: A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing the safety and efficacy of aprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric participants has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy Induced Nausea and Vomiting | Phase 3 | Status: COMPLETED | Results posted: 2014-04-04